$PDS

PRECISION DRILLING Corp (PDS) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PRECISION DRILLING CORPORATION Third Quarter Report for the three and nine months ended September 30, 2026 and 2025 This report is dated October 27, 2026, and contains “forward-looking information and statements” within the meaning of applicable securities laws. For

Precision Drilling reported Q3 2026 revenue up 15% to $532M, Adjusted EBITDA up 6% to $125M, and net earnings of $21M, driven by higher North American activity. U.S. rigs increased 19% and margins are expected to rise 30% in Q4. Capital spending was $82M, with the 2026 budget revised to $275M-$285M. The company repurchased $31M of shares and plans upgrades for 25 rigs. Management expects strong 2027 performance, with high utilization in Canada and improved U.S. margins.

TD Securities upgraded Precision Drilling (PDS) to Buy, raising its price target from $116 to $150. The stock is currently trading at $91.27, which is 28% above its GF Value™ of $71.30. The company has a GF Score™ of 73, indicating fair performance, with strengths in growth but weaknesses in momentum. Four gurus hold PDS, with three trimming their positions.

TD Cowen upgraded Precision Drilling (PDS, PD) to Buy, raising its price target to C$150.00. The firm expects U.S. margin recovery in Q4 2026 and sees the stock as undervalued. Precision reported Q2 revenue of $452.8M, beating estimates, but EPS missed due to reactivation costs. The company aims to improve margins and return cash to shareholders.

Precision Drilling (TSX: PD, NYSE: PDS) received approval for a Normal Course Issuer Bid to buy back up to 1,229,799 shares (10% of public float) by September 20, 2027. The company has already repurchased 668,674 shares at an average price of CAD$102.54. Purchases will be funded from available resources and may commence on September 21, 2026.

PDS Biotechnology raised $22.6 million in equity funding, causing its shares to rise. The company recently announced the departure of its Chief Operating Officer, Stephan Toutain. The stock has seen significant volatility, with a 30% increase over 5 days and a 40.93% gain year-to-date, but a 62.65% decline over a longer period.

The U.S. has granted North American Blue Energy Partners (NABEP) 100-year concessions for 17 Venezuelan oil fields with 65 billion barrels of reserves. The U.S. gains equity and governance rights. NABEP plans to deploy 52 drilling rigs, with some already acquired from Helmerich & Payne, Patterson-UTI Energy, and Precision Drilling. China has responded, asserting its legal rights in Venezuela. Halliburton and ExxonMobil are key players in the potential U.S.-led oil development.

PDS Biotechnology announced that Lars Boesgaard will step down as CFO on September 12. The company has not yet named a replacement. Boesgaard's departure may impact investor confidence in the company's leadership stability.

PDS Ltd’s Q1 2027 earnings call highlighted 15% revenue growth to Rs 3,444 crore and a stronger order book, with management expecting continued revenue and GMV momentum. The CEO cited new sourcing-as-a-service contracts with up to US$330 million annual potential and said working capital improved structurally to about one day. Finance costs were discussed in relation to early payment discounts.

PDS Limited reported Q1 FY27 consolidated results, with revenue up 14.8% YoY to ₹3,444 crore. The company said GMV rose 11.1% to ₹5,146 crore and the order book increased 23% to ₹6,095 crore. Gross margin expanded 63 bps, PAT grew 42.7%, net debt fell 73% to ₹29 crore, and net working capital improved to 1 day.